Board of Directors

Magnus Persson

Chairman of the Board since 2016, born 1960. Chairman of the Remuneration Committee and Member of the Drug Development Committee. Number of shares: 262 743

Magnus Persson is MD and associate professor in physiology at the Karolinska Institute in Stockholm. Persson has extensive experience of financing within the fields of medicine, life sciences and biotech. Persson has previously led development teams in clinical phase II and phase III programmes in the pharmaceutical industry and has founded and led private as well as public biotech and medtech companies, either as Chairman or Member of the Board, in Europe and the US. Persson has also been involved in multiple IPOs.
Persson is Chairman of the Board of Eir Ventures Partners AB and associated companies, Attgeno AB, Initiator Pharma AS, and Board Member of Avalo Inc.

Independent in relation to the Company and its management and the Company’s major shareholders.

Anders Martin-Löf

Board member since 2018, born 1971. Chairman of the Audit Committee. Number of shares: 75 000

Anders Martin-Löf is the CFO of BioArctic AB and Board Member of Affibody Medical AB. He has extensive experience as CFO for companies listed on the Stockholm stock exchange and has served as CFO for Oncopeptides AB, Wilson Therapeutics AB and RaySearch Laboratories AB. Martin-Löf has also held the position of Head of Investor Relations and different positions within business development at Swedish Orphan Biovitrum. Martin-Löf holds an MSc in Engineering Physics from the Royal Institute of Technology and a BSc in Business Administration and Economics from Stockholm University.

Independent in relation to the Company and its management and the Companys major shareholders.

Flavia Borellini

Board member since 2020, born 1959. Chairman of the Drug Development Committee. Number of shares: 0

Flavia Borellini holds a PhD in Pharmaceutical Chemistry and Technology from the University of Modena in Italy.
Borellini has broad experience in oncology and other therapeutic areas and has held senior positions at Astra Zeneca (Global Franchise Head, Hematology and Vice President, Global Product and Portfolio Strategy), Acerta Pharma (CEO), ONYX Pharmaceuticals (Vice President, Program Leadership), and Roche/Genetech (Lifecycle Leader). Borellini serves as a Member of the Board of Directors of Kartos Therapeutics, Revolution Medicines and Viracta.

Independent in relation to the Company and its management and the Company’s major shareholders.

Damian Marron

Board member since 2021, born 1962. Number of shares: 63 054

Damian Marron has extensive experience as a Board Member and CEO within the life science industry, with a successful track record of leadership and value creation in public and private biotechnology companies. Marron has held positions as CEO and Executive Vice President in several biotech companies. He is currently Chairman of the Board of Targovax ASA, Imophoron Ltd, Indegra Therapeutics Ltd and Board Member of Resolys Bio Inc. and Onya Therapeutics Ltd, and Head of Biopharma at Treehill Partners.
Marron holds a BSc degree in Pharmacology from the University of Liverpool.

Independent in relation to the Companys major shareholders

Jenny Sundqvist

Board member since 2025, born 1971. Member of the Audit Committee. Number of shares: 0

Jenny Sundqvist is CEO of Navinci Diagnostics AB and has been active in the pharmaceuticals and biotechnology industry for more than 25 years. Sundqvist has experience in drug development and has worked in several therapeutic areas. She has been CEO of the listed company InDex Pharmaceuticals, held senior positions at Isofol Medical, AstraZeneca, Gambro and Orrefors Kosta Boda. Sundqvist has a Master of Business Administration from the University of Texas.

Independent in relation to the Company and its management and the Company’s major shareholders.